Armstrong, A. W., Hee Park, S., Chirikov, V., Nicolas, P., Wang, W.-J., Colombo, M. J., & Patel, V. (2022). Optimizing the treatment sequence: the cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial. SKIN The Journal of Cutaneous Medicine, 6(6), s62. https://doi.org/10.25251/skin.6.supp.62